In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its ...

Shares of Novo Nordisk ($NVO) are up 3% at the time of writing after the Centers for Medicare & Medicaid Services (CMS) ...

The Trump administration’s negotiation with Novo Nordisk A/S that slashes 71% off the list price of its blockbusters Ozempic ...

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the Inflation Reduction ...

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include ...

Discover why Novo Nordisk’s stagnating growth and lower obesity drug efficacy may signal more downside risk for investors.

The lower prices stem from the Medicare negotiation program created under the Biden administration's Inflation Reduction Act.

Medicare has negotiated steep new prices for 15 high-cost drugs, including Novo Nordisk’s blockbuster semaglutide (Wegovy and Ozempic), with negotiated prices set to take effect in 2027. The move cuts ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of the program’s price negotiations, touting a total of $12 billion ...